Letrozole Teva

Letrozole, the active ingredient in Letrozole Teva, is an aromatase inhibitor presented as an oral tablet for oral use. It is indicated for the treatment of estrogen‑receptor‑positive breast cancer in postmenopausal women, where it lowers estrogen synthesis to help control tumor growth. The drug works by competitively inhibiting the aromatase enzyme, thereby reducing peripheral conversion of androgens to estrogens.

GNH USA supplies Letrozole Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Letrozole is used in the hormonal pathway of estrogen‑dependent breast cancer.

- Estrogen receptor‑positive breast cancer (postmenopausal): Reduces tumor progression by lowering circulating estrogen levels. - Adjuvant therapy for early‑stage disease: Decreases risk of recurrence after surgery and radiotherapy. - Metastatic breast cancer: Helps control disease spread in hormone‑responsive tumors.

Common side effects are generally mild to moderate and may affect treatment tolerability.

Common Side Effects: - Hot flashes: Sudden feeling of warmth, often with sweating. - Arthralgia: Joint pain or stiffness. - Fatigue: Persistent tiredness not relieved by rest. - Nausea: Mild stomach upset. - Headache: Pressure or throbbing pain. - Insomnia: Difficulty falling or staying asleep.

Serious or Rare Side Effects: - Severe liver injury: Jaundice, dark urine, or elevated liver enzymes. - Bone fracture: Increased risk of osteoporosis‑related breaks. - Pulmonary embolism: Sudden shortness of breath, chest pain. - Anaphylaxis: Rapid swelling, hives, or difficulty breathing. - QT interval prolongation: Potential cardiac arrhythmia.

Patients should be monitored for specific safety concerns before and during therapy.

- Bone health monitoring: Assess bone mineral density periodically. - Liver function testing: Check hepatic enzymes at baseline and during treatment. - Cardiovascular assessment: Evaluate risk factors for thrombosis and embolism. - Pregnancy avoidance: Contraindicated in pregnancy; ensure effective contraception. - Menopausal symptom counseling: Discuss hot flashes and mood changes. - Store at below 25°C: Keep in the original packaging, protect from moisture and direct light.

Letrozole may interact with other medicines that affect its metabolism or hormonal activity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): Can markedly reduce letrozole exposure. - Exogenous estrogen therapy: May counteract the drug’s aromatase inhibition. - Tamoxifen: Potential antagonistic effect on estrogen pathways.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., fluconazole): May increase plasma levels modestly. - Warfarin: Enhanced anticoagulant effect; monitor INR. - Statins metabolized by CYP3A4: Observe for altered lipid‑lowering response. - SSRIs (e.g., fluoxetine): Possible additive effect on QT interval. - Antihypertensives: Monitor blood pressure as hormonal changes can influence vascular tone.